List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7676265/publications.pdf Version: 2024-02-01

	30047	37183
12,082	54	96
citations	h-index	g-index
070	070	10000
273	273	19038
docs citations	times ranked	citing authors
	citations 273	12,082 54 citations h-index 273 273

#	Article	IF	CITATIONS
1	Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical libraries. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11473-11478.	3.3	733
2	Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nature Medicine, 2016, 22, 1101-1107.	15.2	581
3	High-throughput screening assays for the identification of chemical probes. Nature Chemical Biology, 2007, 3, 466-479.	3.9	555
4	Phenotypic screens as a renewed approach for drug discovery. Drug Discovery Today, 2013, 18, 1067-1073.	3.2	363
5	Application of Real-Time Cell Electronic Sensing (RT-CES) Technology to Cell-Based Assays. Assay and Drug Development Technologies, 2004, 2, 363-372.	0.6	343
6	Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium. Cell Stem Cell, 2020, 27, 937-950.e9.	5.2	314
7	Drug combination therapy increases successful drug repositioning. Drug Discovery Today, 2016, 21, 1189-1195.	3.2	284
8	Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia. Cancer Cell, 2015, 27, 864-876.	7.7	265
9	Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerging Microbes and Infections, 2014, 3, 1-7.	3.0	200
10	A New Glucocerebrosidase Chaperone Reduces Â-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. Journal of Neuroscience, 2016, 36, 7441-7452.	1.7	189
11	Drug repurposing screens and synergistic drugâ€combinations for infectious diseases. British Journal of Pharmacology, 2018, 175, 181-191.	2.7	181
12	Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. Cell Discovery, 2020, 6, 80.	3.1	172
13	Increased Expression of the Cardiac L-type Calcium Channel in Estrogen Receptor–deficient Mice. Journal of General Physiology, 1997, 110, 135-140.	0.9	165
14	Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening. ACS Pharmacology and Translational Science, 2020, 3, 1008-1016.	2.5	162
15	Elabela-Apelin Receptor Signaling Pathway is Functional in Mammalian Systems. Scientific Reports, 2015, 5, 8170.	1.6	156
16	Molecular signatures associated with ZIKV exposure in human cortical neural progenitors. Nucleic Acids Research, 2016, 44, 8610-8620.	6.5	155
17	Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13192-13197.	3.3	139
18	RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery. SLAS Discovery, 2020, 25, 1141-1151.	1.4	131

#	Article	IF	CITATIONS
19	Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. Cell Discovery, 2018, 4, 31.	3.1	128
20	A Robotic Platform for Quantitative High-Throughput Screening. Assay and Drug Development Technologies, 2008, 6, 637-657.	0.6	126
21	Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor. Journal of Biological Chemistry, 1998, 273, 15687-15692.	1.6	123
22	High Throughput Assay Technologies for Ion Channel Drug Discovery. Assay and Drug Development Technologies, 2004, 2, 543-552.	0.6	120
23	Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Science Translational Medicine, 2015, 7, 282ra49.	5.8	118
24	Discovery, Structure–Activity Relationship, and Biological Evaluation of Noninhibitory Small Molecule Chaperones of Glucocerebrosidase. Journal of Medicinal Chemistry, 2012, 55, 5734-5748.	2.9	113
25	Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1–CBFβ interaction. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14592-14597.	3.3	108
26	Collaborative Development of 2-Hydroxypropyl-β-Cyclodextrin for the Treatment of Niemann-Pick Type C1 Disease. Current Topics in Medicinal Chemistry, 2014, 14, 330-339.	1.0	108
27	Î'-Tocopherol Reduces Lipid Accumulation in Niemann-Pick Type C1 and Wolman Cholesterol Storage Disorders. Journal of Biological Chemistry, 2012, 287, 39349-39360.	1.6	107
28	Cardiac Glycosides Inhibit p53 Synthesis by a Mechanism Relieved by Src or MAPK Inhibition. Cancer Research, 2009, 69, 6556-6564.	0.4	105
29	Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12471-12476.	3.3	102
30	A cost-effective and efficient reprogramming platform for large-scale production of integration-free human induced pluripotent stem cells in chemically defined culture. Scientific Reports, 2015, 5, 11319.	1.6	96
31	Macrophage Models of Gaucher Disease for Evaluating Disease Pathogenesis and Candidate Drugs. Science Translational Medicine, 2014, 6, 240ra73.	5.8	94
32	Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles. ACS Pharmacology and Translational Science, 2020, 3, 1165-1175.	2.5	94
33	Chemical signatures and new drug targets for gametocytocidal drug development. Scientific Reports, 2014, 4, 3743.	1.6	89
34	Effects of SARSâ€CoVâ€2 mutations on protein structures and intraviral protein–protein interactions. Journal of Medical Virology, 2021, 93, 2132-2140.	2.5	85
35	Drug Discovery Strategies for SARS-CoV-2. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 127-138.	1.3	83
36	Scintillation proximity assay of inositol phosphates in cell extracts: High-throughput measurement of G-protein-coupled receptor activation. Analytical Biochemistry, 2003, 313, 311-318.	1.1	82

#	Article	IF	CITATIONS
37	Synergistic and Antagonistic Drug Combinations against SARS-CoV-2. Molecular Therapy, 2021, 29, 873-885.	3.7	78
38	Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nature Communications, 2013, 4, 2044.	5.8	76
39	Synergistic drug combination effectively blocks Ebola virus infection. Antiviral Research, 2017, 137, 165-172.	1.9	75
40	The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules. ACS Infectious Diseases, 2021, 7, 1389-1408.	1.8	74
41	Niemann–Pick Disease Type C: Induced Pluripotent Stem Cell–Derived Neuronal Cells for Modeling Neural Disease and Evaluating Drug Efficacy. Journal of Biomolecular Screening, 2014, 19, 1164-1173.	2.6	73
42	Methyl-β-cyclodextrin restores impaired autophagy flux in Niemann-Pick C1-deficient cells through activation of AMPK. Autophagy, 2017, 13, 1435-1451.	4.3	73
43	Compound Management for Quantitative High-Throughput Screening. Journal of the Association for Laboratory Automation, 2008, 13, 79-89.	2.8	72
44	High-Throughput Screening to Identify Compounds That Increase Fragile X Mental Retardation Protein Expression in Neural Stem Cells Differentiated From Fragile X Syndrome Patient-Derived Induced Pluripotent Stem Cells. Stem Cells Translational Medicine, 2015, 4, 800-808.	1.6	70
45	High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines. Human Molecular Genetics, 2014, 23, 1551-1562.	1.4	69
46	Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2. Frontiers in Pharmacology, 2020, 11, 592737.	1.6	69
47	Drug combination therapy for emerging viral diseases. Drug Discovery Today, 2021, 26, 2367-2376.	3.2	65
48	Drug discovery and development for rare genetic disorders. American Journal of Medical Genetics, Part A, 2017, 173, 2307-2322.	0.7	64
49	Induced pluripotent stem cells for neural drug discovery. Drug Discovery Today, 2019, 24, 992-999.	3.2	63
50	A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel. Analytical Biochemistry, 2009, 394, 30-38.	1.1	62
51	High Throughput Screening for Small Molecule Therapy for Gaucher Disease Using Patient Tissue as the Source of Mutant Glucocerebrosidase. PLoS ONE, 2012, 7, e29861.	1.1	62
52	Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Research, 2015, 17, 59.	2.2	61
53	DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer. Cancer Letters, 2018, 428, 104-116.	3.2	60
54	Quantitative High-Throughput Screening Using a Live-Cell cAMP Assay Identifies Small-Molecule Agonists of the TSH Receptor. Journal of Biomolecular Screening, 2008, 13, 120-127.	2.6	59

#	Article	IF	CITATIONS
55	Evaluation of Quinazoline Analogues as Glucocerebrosidase Inhibitors with Chaperone Activity. Journal of Medicinal Chemistry, 2011, 54, 1033-1058.	2.9	59
56	Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria. Emerging Microbes and Infections, 2016, 5, 1-11.	3.0	59
57	Zika Virus: Origins, Pathological Action, and Treatment Strategies. Frontiers in Microbiology, 2018, 9, 3252.	1.5	58
58	Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. Science Translational Medicine, 2018, 10, .	5.8	55
59	A Cell-Based Ultra-High-Throughput Screening Assay for Identifying Inhibitors of D-Amino Acid Oxidase. Journal of Biomolecular Screening, 2006, 11, 481-487.	2.6	54
60	Identification and optimization of small-molecule agonists of the human relaxin hormone receptor RXFP1. Nature Communications, 2013, 4, 1953.	5.8	54
61	Dietary Fat Intake and Lung Cancer Risk: A Pooled Analysis. Journal of Clinical Oncology, 2017, 35, 3055-3064.	0.8	52
62	Structural Basis for Inactivation of Giardia lamblia Carbamate Kinase by Disulfiram. Journal of Biological Chemistry, 2014, 289, 10502-10509.	1.6	51
63	A Phenotypic Compound Screening Assay for Lysosomal Storage Diseases. Journal of Biomolecular Screening, 2014, 19, 168-175.	2.6	51
64	Improving therapy of severe infections through drug repurposing of synergistic combinations. Current Opinion in Pharmacology, 2019, 48, 92-98.	1.7	51
65	Two high-throughput screening assays for aberrant RNA–protein interactions in myotonic dystrophy type 1. Analytical and Bioanalytical Chemistry, 2012, 402, 1889-1898.	1.9	49
66	Inhibition of PIP4K \hat{I}^3 ameliorates the pathological effects of mutant huntingtin protein. ELife, 2017, 6, .	2.8	49
67	An AlphaScreenâ"¢-Based High-Throughput Screen to Identify Inhibitors of Hsp90-Cochaperone Interaction. Journal of Biomolecular Screening, 2009, 14, 273-281.	2.6	47
68	Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects. Nucleic Acids Research, 2014, 42, 6591-6602.	6.5	46
69	A quantitative high throughput assay for identifying gametocytocidal compounds. Molecular and Biochemical Parasitology, 2013, 188, 20-25.	0.5	45
70	High-Throughput <i>Giardia lamblia</i> Viability Assay Using Bioluminescent ATP Content Measurements. Antimicrobial Agents and Chemotherapy, 2011, 55, 667-675.	1.4	43
71	Astrocytes as targets for drug discovery. Drug Discovery Today, 2018, 23, 673-680.	3.2	43
72	Fabry Disease – Current Treatment and New Drug Development. Current Chemical Genomics, 2010, 4, 50-56.	2.0	42

#	Article	lF	CITATIONS
73	Targeting Wolman Disease and Cholesteryl Ester Storage Disease: Disease Pathogenesis and Therapeutic Development. Current Chemical Genomics and Translational Medicine, 2017, 11, 1-18.	4.3	42
74	Discovery, Synthesis, and Biological Evaluation of Novel SMN Protein Modulators. Journal of Medicinal Chemistry, 2011, 54, 6215-6233.	2.9	38
75	Biological activity-based modeling identifies antiviral leads against SARS-CoV-2. Nature Biotechnology, 2021, 39, 747-753.	9.4	38
76	ERK Regulates HIF1α-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer. Clinical Cancer Research, 2019, 25, 5947-5960.	3.2	37
77	Repurposing Screen Identifies Unconventional Drugs With Activity Against Multidrug Resistant Acinetobacter baumannii. Frontiers in Cellular and Infection Microbiology, 2018, 8, 438.	1.8	37
78	Application of Division Arrest Technology to Cell-Based HTS: Comparison with Frozen and Fresh Cells. Assay and Drug Development Technologies, 2005, 3, 17-26.	0.6	36
79	Optimization and Validation of Two Miniaturized Glucocerebrosidase Enzyme Assays for High Throughput Screening. Combinatorial Chemistry and High Throughput Screening, 2008, 11, 817-824.	0.6	35
80	Treatment Paradigms for Retinal and Macular Diseases Using 3-D Retina Cultures Derived From Human Reporter Pluripotent Stem Cell Lines. , 2016, 57, ORSFI1.		35
81	Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels. Toxicology and Applied Pharmacology, 2011, 252, 250-258.	1.3	34
82	Disease models for the development of therapies for lysosomal storage diseases. Annals of the New York Academy of Sciences, 2016, 1371, 15-29.	1.8	34
83	A novel quantitative high-throughput screen identifies drugs that both activate SUMO conjugation via the inhibition of microRNAs 182 and 183 and facilitate neuroprotection in a model of oxygen and glucose deprivation. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 426-441.	2.4	34
84	Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease. Orphanet Journal of Rare Diseases, 2018, 13, 152.	1.2	34
85	Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death. Bioorganic and Medicinal Chemistry, 2009, 17, 5139-5145.	1.4	33
86	Identification of a Selective Small-Molecule Inhibitor Series Targeting the Eyes Absent 2 (Eya2) Phosphatase Activity. Journal of Biomolecular Screening, 2013, 18, 85-96.	2.6	33
87	Discovery of Novel Antigiardiasis Drug Candidates. Antimicrobial Agents and Chemotherapy, 2014, 58, 7303-7311.	1.4	33
88	Pluripotent Stem Cell Platforms for Drug Discovery. Trends in Molecular Medicine, 2018, 24, 805-820.	3.5	33
89	Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 3582-3594.	2.9	32
90	Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space. ACS Central Science, 2018, 4, 1727-1741.	5.3	32

#	Article	IF	CITATIONS
91	Comparison on Functional Assays for Gq-Coupled GPCRs by Measuring Inositol Monophospate-1 and Intracellular Calcium in 1536-Well Plate Format. Current Chemical Genomics, 2008, 1, 70-78.	2.0	32
92	A high throughput glucocerebrosidase assay using the natural substrate glucosylceramide. Analytical and Bioanalytical Chemistry, 2012, 402, 731-739.	1.9	31
93	High-Throughput Phenotypic Screening of Human Astrocytes to Identify Compounds That Protect Against Oxidative Stress. Stem Cells Translational Medicine, 2016, 5, 613-627.	1.6	31
94	Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance. Oncogene, 2018, 37, 3981-3997.	2.6	31
95	Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses. Orphanet Journal of Rare Diseases, 2018, 13, 54.	1.2	31
96	A 1,536-Well cAMP Assay for Gs- and Gi-Coupled Receptors Using Enzyme Fragmentation Complementation. Assay and Drug Development Technologies, 2004, 2, 39-49.	0.6	30
97	Identification of small molecule antagonists of the human mas-related gene-X1 receptor. Analytical Biochemistry, 2006, 351, 50-61.	1.1	30
98	N4-Phenyl modifications of N2-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5783-5789.	1.0	30
99	Novel Cell-Based Hepatitis C Virus Infection Assay for Quantitative High-Throughput Screening of Anti-Hepatitis C Virus Compounds. Antimicrobial Agents and Chemotherapy, 2014, 58, 995-1004.	1.4	30
100	Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. Journal of Medicinal Chemistry, 2016, 59, 841-853.	2.9	30
101	Fluorescent Proteinâ€Based Cellular Assays Analyzed by Laserâ€5canning Microplate Cytometry in 1536â€Well Plate Format. Methods in Enzymology, 2006, 414, 566-589.	0.4	29
102	A Multiplex Calcium Assay for Identification of GPCR Agonists and Antagonists. Assay and Drug Development Technologies, 2010, 8, 362-374.	0.6	29
103	ERK and β-Arrestin Interaction: A Converging Point of Signaling Pathways for Multiple Types of Cell Surface Receptors. Journal of Biomolecular Screening, 2015, 20, 341-349.	2.6	29
104	Induced Pluripotent Stem Cells for Disease Modeling and Evaluation of Therapeutics for Niemann-Pick Disease Type A. Stem Cells Translational Medicine, 2016, 5, 1644-1655.	1.6	29
105	Quantitative highâ€throughput screening identifies cytoprotective molecules that enhance SUMO conjugation <i>via</i> the inhibition of SUMOâ€specific protease (SENP)2. FASEB Journal, 2018, 32, 1677-1691.	0.2	29
106	Enrichment of NPC1-deficient cells with the lipid LBPA stimulates autophagy, improves lysosomal function, and reduces cholesterol storage. Journal of Biological Chemistry, 2021, 297, 100813.	1.6	29
107	A Collaborative Screening Program for the Discovery of Inhibitors of HCV NS2/3 cis-Cleaving Protease Activity. Journal of Biomolecular Screening, 2002, 7, 149-154.	2.6	28
108	The Pilot Phase of the NIH Chemical Genomics Center. Current Topics in Medicinal Chemistry, 2009, 9, 1181-1193.	1.0	28

#	Article	IF	CITATIONS
109	Discovery of a Novel Noniminosugar Acid α Glucosidase Chaperone Series. Journal of Medicinal Chemistry, 2012, 55, 7546-7559.	2.9	27
110	A Novel Brain Penetrant NPS Receptor Antagonist, NCGC00185684, Blocks Alcohol-Induced ERK-Phosphorylation in the Central Amygdala and Decreases Operant Alcohol Self-Administration in Rats. Journal of Neuroscience, 2013, 33, 10132-10142.	1.7	27
111	Identification of Small-Molecule Agonists of Human Relaxin Family Receptor 1 (RXFP1) by Using a Homogenous Cell-Based cAMP Assay. Journal of Biomolecular Screening, 2013, 18, 670-677.	2.6	27
112	Discovery, Optimization, and Characterization of Novel D ₂ Dopamine Receptor Selective Antagonists. Journal of Medicinal Chemistry, 2014, 57, 3450-3463.	2.9	27
113	A High-Throughput Screening Assay for Fungicidal Compounds against Cryptococcus neoformans. Journal of Biomolecular Screening, 2014, 19, 270-277.	2.6	27
114	Advancing precision medicine with personalized drug screening. Drug Discovery Today, 2019, 24, 272-278.	3.2	27
115	Zika Virus-Induced Neuronal Apoptosis via Increased Mitochondrial Fragmentation. Frontiers in Microbiology, 2020, 11, 598203.	1.5	27
116	Miniaturization of a Hepatitis C Virus RNA Polymerase Assay Using a â^'102°C Cooled CCD Camera-Based Imaging System. Analytical Biochemistry, 2001, 290, 214-220.	1.1	26
117	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA. Journal of Medicinal Chemistry, 2019, 62, 6175-6189.	2.9	26
118	Automated High-Content Screening for Compounds That Disassemble the Perinucleolar Compartment. Journal of Biomolecular Screening, 2009, 14, 1045-1053.	2.6	25
119	Selective Modulation of Gq/Gs pathways by Naphtho Pyrano Pyrimidines As Antagonists of the Neuropeptide S Receptor. ACS Chemical Neuroscience, 2010, 1, 559-574.	1.7	25
120	Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics. Scientific Reports, 2021, 11, 6725.	1.6	25
121	A High-Throughput Screening Assay for Determining Cellular Levels of Total Tau Protein. Current Alzheimer Research, 2013, 10, 679-687.	0.7	25
122	Evaluation of 2-thioxo-2,3,5,6,7,8-hexahydropyrimido[4,5-d]pyrimidin-4(1H)-one analogues as GAA activators. European Journal of Medicinal Chemistry, 2010, 45, 1880-1897.	2.6	24
123	A new resorufin-based α-glucosidase assay for high-throughput screening. Analytical Biochemistry, 2009, 390, 79-84.	1.1	23
124	High-Throughput Screening, Discovery, and Optimization To Develop a Benzofuran Class of Hepatitis C Virus Inhibitors. ACS Combinatorial Science, 2015, 17, 641-652.	3.8	23
125	Maduramicin Rapidly Eliminates Malaria Parasites and Potentiates the Gametocytocidal Activity of the Pyrazoleamide PA21A050. Antimicrobial Agents and Chemotherapy, 2016, 60, 1492-1499.	1.4	23
126	Patient iPSC-derived neural stem cells exhibit phenotypes in concordance with the clinical severity of mucopolysaccharidosis I. Human Molecular Genetics, 2018, 27, 3612-3626.	1.4	23

#	Article	IF	CITATIONS
127	Rapid Identification of Antifungal Compounds against Exserohilum rostratum Using High Throughput Drug Repurposing Screens. PLoS ONE, 2013, 8, e70506.	1.1	23
128	Multi-Gram Scale Synthesis of FR180204. Journal of Organic Chemistry, 2009, 74, 8870-8873.	1.7	22
129	Non-iminosugar glucocerebrosidase small molecule chaperones. MedChemComm, 2012, 3, 56-60.	3.5	22
130	An Alternative Direct Compound Dispensing Method Using the HP D300 Digital Dispenser. Journal of the Association for Laboratory Automation, 2013, 18, 367-374.	2.8	22
131	Structural interaction between DISC1 and ATF4 underlying transcriptional and synaptic dysregulation in an iPSC model of mental disorders. Molecular Psychiatry, 2021, 26, 1346-1360.	4.1	22
132	High-Throughput Multiplexed Quantitation of Protein Aggregation and Cytotoxicity in a Huntington's Disease Model. Current Chemical Genomics, 2012, 6, 79-86.	2.0	22
133	A Cell-Based PDE4 Assay in 1536-Well Plate Format for High-Throughput Screening. Journal of Biomolecular Screening, 2008, 13, 609-618.	2.6	21
134	High-Throughput Viability Assay Using an Autonomously Bioluminescent Cell Line with a Bacterial Lux Reporter. Journal of the Association for Laboratory Automation, 2015, 20, 164-174.	2.8	21
135	Highâ€ŧhroughput screening assays for SARS oVâ€2 drug development: Current status and future directions. Drug Discovery Today, 2021, 26, 2439-2444.	3.2	21
136	Evaluation of Cholesterol Reduction Activity of Methyl-β-cyclodextrin Using Differentiated Human Neurons and Astrocytes. Journal of Biomolecular Screening, 2012, 17, 1243-1251.	2.6	20
137	Plasma and Tissue Concentrations of α-Tocopherol and δ-Tocopherol Following High Dose Dietary Supplementation in Mice. Nutrients, 2012, 4, 467-490.	1.7	20
138	Mitochondrial DNA damage by bleomycin induces AML cell death. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 811-820.	2.2	20
139	High throughput cell-based assay for identification of glycolate oxidase inhibitors as a potential treatment for Primary Hyperoxaluria Type 1. Scientific Reports, 2016, 6, 34060.	1.6	20
140	Rho GTPases: RAC1 polymorphisms affected platinum-based chemotherapy toxicity in lung cancer patients. Cancer Chemotherapy and Pharmacology, 2016, 78, 249-258.	1.1	20
141	Identification of Multiple Cryptococcal Fungicidal Drug Targets by Combined Gene Dosing and Drug Affinity Responsive Target Stability Screening. MBio, 2016, 7, .	1.8	19
142	Torin 2 Derivative, NCATS-SM3710, Has Potent Multistage Antimalarial Activity through Inhibition of <i>P. falciparum</i> Phosphatidylinositol 4-Kinase (<i>Pf</i> â€PI4KIIIβ). ACS Pharmacology and Translational Science, 2020, 3, 948-964.	2.5	19
143	Identification of Antifungal Compounds against Multidrug-Resistant Candida auris Utilizing a High-Throughput Drug-Repurposing Screen. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	19
144	Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development. Journal of Pharmacology and Experimental Therapeutics, 2021, 378, 166-172.	1.3	19

#	Article	IF	CITATIONS
145	Structure–Activity Relationship of Imidazopyridinium Analogues as Antagonists of Neuropeptide S Receptor. Journal of Medicinal Chemistry, 2013, 56, 9045-9056.	2.9	18
146	Neural stem cells for disease modeling of Wolman disease and evaluation of therapeutics. Orphanet Journal of Rare Diseases, 2017, 12, 120.	1.2	18
147	2-Arylindole-3-acetamides. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 865-869.	1.0	17
148	Analytical Characterization of Methyl-β-Cyclodextrin for Pharmacological Activity to Reduce Lysosomal Cholesterol Accumulation in Niemann-Pick Disease Type C1 Cells. Assay and Drug Development Technologies, 2017, 15, 154-166.	0.6	17
149	High Throughput Screening for Inhibitors of Alpha-Galactosidase. Current Chemical Genomics, 2010, 4, 67-73.	2.0	16
150	Discovery of Small Molecule Entry Inhibitors Targeting the Fusion Peptide of SARS-CoV-2 Spike Protein. ACS Medicinal Chemistry Letters, 2021, 12, 1267-1274.	1.3	16
151	ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice. JCI Insight, 2016, 1, e88427.	2.3	16
152	A High Throughput Screening Assay System for the Identification of Small Molecule Inhibitors of gsp. PLoS ONE, 2014, 9, e90766.	1.1	16
153	A Homogenous Luminescence Assay Reveals Novel Inhibitors for Giardia LambliaCarbamate Kinase. Current Chemical Genomics, 2012, 6, 93-102.	2.0	16
154	A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry. SLAS Discovery, 2022, 27, 86-94.	1.4	16
155	Repurposing drugs as COVID-19 therapies: A toxicity evaluation. Drug Discovery Today, 2022, 27, 1983-1993.	3.2	16
156	A Miniaturized Glucocorticoid Receptor Translocation Assay Using Enzymatic Fragment Complementation Evaluated with qHTS. Combinatorial Chemistry and High Throughput Screening, 2008, 11, 545-559.	0.6	15
157	A High-Throughput, Multi-Cell Phenotype Assay for the Identification of Novel Inhibitors of Chemotaxis/Migration. Scientific Reports, 2016, 6, 22273.	1.6	15
158	Repurposing a novel parathyroid hormone analogue to treat hypoparathyroidism. British Journal of Pharmacology, 2018, 175, 262-271.	2.7	15
159	Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids. Drug Discovery Today, 2019, 24, 2126-2138.	3.2	15
160	Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection. Bioorganic and Medicinal Chemistry Letters, 2021, 40, 127906.	1.0	15
161	Efficient Identification of Anti-SARS-CoV-2 Compounds Using Chemical Structure- and Biological Activity-Based Modeling. Journal of Medicinal Chemistry, 2022, 65, 4590-4599.	2.9	15
162	Mechanism of HERG potassium channel inhibition by tetra-n-octylammonium bromide and benzethonium chloride. Toxicology and Applied Pharmacology, 2013, 267, 155-166.	1.3	14

#	Article	IF	CITATIONS
163	Novel lead structures with both Plasmodium falciparum gametocytocidal and asexual blood stage activity identified from high throughput compound screening. Malaria Journal, 2017, 16, 147.	0.8	14
164	Quantitative Chemotherapeutic Profiling of Gynecologic Cancer Cell Lines Using Approved Drugs and Bioactive Compounds. Translational Oncology, 2019, 12, 441-452.	1.7	14
165	SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance. Cell Death and Disease, 2021, 12, 341.	2.7	13
166	Modeling CNS Involvement in Pompe Disease Using Neural Stem Cells Generated from Patient-Derived Induced Pluripotent Stem Cells. Cells, 2021, 10, 8.	1.8	13
167	Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. Journal of Medicinal Chemistry, 2017, 60, 6364-6383.	2.9	12
168	High-Throughput Screening of 11β-Hydroxysteroid Dehydrogenase Type 1 in Scintillation Proximity Assay Format. Assay and Drug Development Technologies, 2005, 3, 377-384.	0.6	11
169	Synthesis and characterization of a new fluorogenic substrate for alpha-galactosidase. Analytical and Bioanalytical Chemistry, 2009, 394, 1903-1909.	1.9	11
170	Novel Patient Cell-Based HTS Assay for Identification of Small Molecules for a Lysosomal Storage Disease. PLoS ONE, 2011, 6, e29504.	1.1	11
171	One-Step Seeding of Neural Stem Cells with Vitronectin-Supplemented Medium for High-Throughput Screening Assays. Journal of Biomolecular Screening, 2016, 21, 1112-1124.	2.6	11
172	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. Antiviral Research, 2020, 173, 104667.	1.9	11
173	Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors. MBio, 2022, 13, e0323821.	1.8	11
174	High-Throughput Cell-Based Screening Using Scintillation Proximity Assay for the Discovery of Inositol Phosphatase Inhibitors. Journal of Biomolecular Screening, 2004, 9, 132-140.	2.6	10
175	In vitro evaluation of imidazo[4,5 -c]quinolin-2-ones as gametocytocidal antimalarial agents. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2907-2911.	1.0	10
176	An induced pluripotent stem cell line (TRNDi009-C) from a Niemann-Pick disease type A patient carrying a heterozygous p.L302P (c.905 T>C) mutation in the SMPD1 gene. Stem Cell Research, 2019, 38, 101461.	0.3	10
177	Generation of an induced pluripotent stem cell line (TRNDi003-A) from a Noonan syndrome with multiple lentigines (NSML) patient carrying a p.Q510P mutation in the PTPN11 gene. Stem Cell Research, 2019, 34, 101374.	0.3	10
178	Development of a High-Throughput Homogeneous AlphaLISA Drug Screening Assay for the Detection of SARS-CoV-2 Nucleocapsid. ACS Pharmacology and Translational Science, 2020, 3, 1233-1241.	2.5	10
179	The synthesis and evaluation of dihydroquinazolin-4-ones and quinazolin-4-ones as thyroid stimulating hormone receptor agonists. MedChemComm, 2011, 2, 1016.	3.5	9
180	Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay. Antiviral Research, 2015, 124, 20-29.	1.9	9

#	Article	IF	CITATIONS
181	Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RXFP1) agonists: Activation results in an antifibrotic gene expression profile. European Journal of Medicinal Chemistry, 2018, 156, 79-92.	2.6	9
182	A human induced pluripotent stem cell line (TRNDi007-B) from an infantile onset Pompe patient carrying p.R854X mutation in the GAA gene. Stem Cell Research, 2019, 37, 101435.	0.3	9
183	Drugging SUMOylation for neuroprotection and oncotherapy. Neural Regeneration Research, 2018, 13, 415.	1.6	9
184	c-Abl Activation Linked to Autophagy-Lysosomal Dysfunction Contributes to Neurological Impairment in Niemann-Pick Type A Disease. Frontiers in Cell and Developmental Biology, 2022, 10, 844297.	1.8	9
185	A high-throughput screening assay for assessing the viability of Cryptococcus neoformans under nutrient starvation conditions. Analytical and Bioanalytical Chemistry, 2013, 405, 6823-6829.	1.9	8
186	Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells. Translational Oncology, 2018, 11, 1053-1064.	1.7	8
187	High-Throughput Zika Viral Titer Assay for Rapid Screening of Antiviral Drugs. Assay and Drug Development Technologies, 2019, 17, 128-139.	0.6	8
188	Mitoxantrone modulates a heparan sulfate-spike complex to inhibit SARS-CoV-2 infection. Scientific Reports, 2022, 12, 6294.	1.6	8
189	A high-throughput sphingomyelinase assay using natural substrate. Analytical and Bioanalytical Chemistry, 2012, 404, 407-414.	1.9	7
190	Efficient Synthesis of 1,9-Substituted Benzo[<i>h</i>][1,6]naphthyridin-2(1 <i>H</i>)-ones and Evaluation of their <i>Plasmodium falciparum</i> Gametocytocidal Activities. ACS Combinatorial Science, 2017, 19, 748-754.	3.8	7
191	Generation of an induced pluripotent stem cell line (TRNDi002-B) from a patient carrying compound heterozygous p.Q208X and p.G310G mutations in the NGLY1 gene. Stem Cell Research, 2019, 34, 101362.	0.3	7
192	Human recombinant lysosomal <scp>βâ€Hexosaminidases</scp> produced in <scp><i>Pichia pastoris</i></scp> efficiently reduced lipid accumulation in <scp>Tayâ€5achs</scp> fibroblasts. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2020, 184, 885-895.	0.7	7
193	An Integrated Systems Biology Approach Identifies the Proteasome as A Critical Host Machinery for ZIKV and DENV Replication. Genomics, Proteomics and Bioinformatics, 2021, 19, 108-122.	3.0	7
194	Therapeutics Development for Alagille Syndrome. Frontiers in Pharmacology, 2021, 12, 704586.	1.6	7
195	Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson's Disease: Pathogenesis and Therapeutic Implications. Frontiers in Aging Neuroscience, 2022, 14, 851135.	1.7	7
196	Therapeutic Strategies For Tay-Sachs Disease. Frontiers in Pharmacology, 0, 13, .	1.6	7
197	Thermodynamic and kinetic aspects of agonist and antagonist binding to 1,4-dihydropyridine receptors. European Journal of Pharmacology, 1991, 208, 137-147.	2.7	6
198	<i>δ</i> -Tocopherol Effect on Endocytosis and Its Combination with Enzyme Replacement Therapy for Lysosomal Disorders: A New Type of Drug Interaction?. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 823-833.	1.3	6

#	Article	IF	CITATIONS
199	17-Hydroxy Wortmannin Restores TRAIL's Response by Ameliorating Increased Beclin 1 Level and Autophagy Function in TRAIL-Resistant Colon Cancer Cells. Molecular Cancer Therapeutics, 2019, 18, 1265-1277.	1.9	6
200	Hybrid <i>In Silico</i> Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants. ACS Pharmacology and Translational Science, 2021, 4, 1675-1688.	2.5	6
201	Identification of potent SENP1 inhibitors that inactivate SENP1/JAK2/STAT signaling pathway and overcome platinum drug resistance in ovarian cancer. Clinical and Translational Medicine, 2021, 11, e649.	1.7	6
202	A Short-Incubation Reporter-Gene Assay for High-Throughput Screening of Estrogen Receptor-α Antagonists. Assay and Drug Development Technologies, 2005, 3, 393-400.	0.6	5
203	Inhibition of HERG potassium channels by domiphen bromide and didecyl dimethylammonium bromide. European Journal of Pharmacology, 2014, 737, 202-209.	1.7	5
204	Identification of 4-phenylquinolin-2(1H)-one as a specific allosteric inhibitor of Akt. Scientific Reports, 2017, 7, 11673.	1.6	5
205	Generation of an induced pluripotent stem cell line (TRNDi008-A) from a Hunter syndrome patient carrying a hemizygous 208insC mutation in the IDS gene. Stem Cell Research, 2019, 37, 101451.	0.3	5
206	Generation of an induced pluripotent stem cell line (TRNDi005-A) from a Mucopolysaccharidosis Type IVA (MPS IVA) patient carrying compound heterozygous p.R61W and p.WT405del mutations in the GALNS gene. Stem Cell Research, 2019, 36, 101408.	0.3	5
207	SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening. ACS Pharmacology and Translational Science, 2022, 5, 8-19.	2.5	5
208	iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II. Experimental Cell Research, 2022, 412, 113007.	1.2	5
209	Evaluation of Micro-Parallel Liquid Chromatography as a Method for HTS-Coupled Actives Verification. Assay and Drug Development Technologies, 2007, 5, 815-824.	0.6	4
210	"Real-Time―High-Throughput Drug and Synergy Testing for Multidrug-Resistant Bacterial Infection: A Case Report. Frontiers in Medicine, 2018, 5, 267.	1.2	4
211	An induced pluripotent stem cell line (TRNDi006-A) from a MPS IIIB patient carrying homozygous mutation of p.Glu153Lys in the NAGLU gene. Stem Cell Research, 2019, 37, 101427.	0.3	4
212	An induced pluripotent stem cell line (TRNDi001-D) from a Niemann-Pick disease type C1 (NPC1) patient carrying a homozygous p. 11061T (c. 3182T>C) mutation in the NPC1 gene. Stem Cell Research, 2020, 44, 101737.	0.3	4
213	Protein structural features predict responsiveness to pharmacological chaperone treatment for three lysosomal storage disorders. PLoS Computational Biology, 2021, 17, e1009370.	1.5	4
214	Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19. ACS Infectious Diseases, 2022, 8, 1191-1203.	1.8	4
215	Discovery and Optimization of Pyrrolopyrimidine Derivatives as Selective Disruptors of the Perinucleolar Compartment, a Marker of Tumor Progression toward Metastasis. Journal of Medicinal Chemistry, 2022, 65, 8303-8331.	2.9	4
216	Generation of an induced pluripotent stem cell line (TRNDi004-I) from a Niemann-Pick disease type B patient carrying a heterozygous mutation of p.L43_A44delLA in the SMPD1 gene. Stem Cell Research, 2019, 37, 101436.	0.3	3

#	Article	IF	CITATIONS
217	Disease modeling for Mucopolysaccharidosis type IIIB using patient derived induced pluripotent stem cells. Experimental Cell Research, 2021, 407, 112785.	1.2	3
218	Phosphodiesterase 4 inhibitors enhance sexual pleasure-seeking activity in rodents. Pharmacology Biochemistry and Behavior, 2011, 98, 349-355.	1.3	2
219	An induced pluripotent stem cell line (TRNDi010-C) from a patient carrying a homozygous p.R401X mutation in the NGLY1 gene. Stem Cell Research, 2019, 39, 101496.	0.3	2
220	Four induced pluripotent stem cell lines (TRNDi021-C, TRNDi023-D, TRNDi024-D and TRNDi025-A) generated from fibroblasts of four healthy individuals. Stem Cell Research, 2020, 49, 102011.	0.3	2
221	Endoclip papillaplasty restores sphincter of Oddi function: Pilot study. Digestive Endoscopy, 2021, 33, 962-969.	1.3	2
222	Generation of an induced pluripotent stem cell line (TRNDi030-A) from a patient with Farber disease carrying a homozygous p. Y36C (c. 107 A>G) mutation in ASAH1. Stem Cell Research, 2021, 53, 102387.	0.3	2
223	Generation of Alagille syndrome derived induced pluripotent stem cell line carrying heterozygous mutation in the JAGGED-1 gene at splicing site (Chr20: 10,629,709C>A) before exon 11. Stem Cell Research, 2021, 53, 102366.	0.3	2
224	Screening Automation. Critical Reviews in Combinatorial Chemistry, 2009, , .	0.1	1
225	Cell-Based No-Wash Fluorescence Assays for Compound Screens Using a Fluorescence Cytometry Plate Reader. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 500-511.	1.3	1
226	Generation of an induced pluripotent stem cell line (TRNDi031-A) from a patient with Alagille syndrome type 1 carrying a heterozygous p. C312X (c. 936ÂTÂ>ÂA) mutation in JAGGED-1. Stem Cell Research, 2021, 54, 102447.	0.3	1
227	Generation of two gene corrected human isogenic iPSC lines (NCATS-CL6104 and NCATS-CL6105) from a patient line (NCATS-CL6103) carrying a homozygous p.R401X mutation in the NGLY1 gene using CRISPR/Cas9. Stem Cell Research, 2021, 56, 102554.	0.3	1
228	Graph Convolutional Network-Based Screening Strategy for Rapid Identification of SARS-CoV-2 Cell-Entry Inhibitors. Journal of Chemical Information and Modeling, 2022, 62, 1988-1997.	2.5	1
229	Enteral extended biliary stents versus conventional plastic biliary stents for the treatment of extrahepatic malignant biliary obstruction: a single-center prospective randomized controlled study. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 8202-8213.	1.3	1
230	Characterization of Calcium Channel Binding. Current Protocols in Pharmacology, 2001, 14, Unit1.25.	4.0	0
231	Drug Combinations. , 2021, , .		0
232	Generation of an induced pluripotent stem cell line (TRNDi012-B) from Fibrodysplasia Ossificans Progressiva (FOP) patient carrying a heterozygous mutation c. 617GÂ>ÂA in the ACVR1 gene. Stem Cell Research, 2021, 54, 102424.	0.3	0
233	An induced pluripotent stem cell line (NCATS-CL9075) from a patient carrying compound heterozygote mutations, p.R390P and p.L318P, in the NGLY1 gene. Stem Cell Research, 2021, 54, 102400.	0.3	0

Small Molecule Drug Discovery for Fabry Disease. , 2010, , 163-177.